The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DNLI | -41.39% | -73.12% | -23.11% | -18% |
| S&P | +14.08% | +93.57% | +14.12% | +158% |
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Analysts maintained their buy ratings on the clinical-stage biotech company.
The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$2.95M | -60.3% |
| Market Cap | $2.12B | -49.1% |
| Market Cap / Employee | $4.11M | 0.0% |
| Employees | 517 | 0.0% |
| Net Income | -$126.90M | -18.4% |
| EBITDA | -$134.49M | -10.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $90.96M | 0.4% |
| Accounts Receivable | $1.90M | 35.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $35.24M | -20.8% |
| Short Term Debt | $9.16M | 14.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -39.75% | -8.0% |
| Return On Invested Capital | -19.82% | 1.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$105.92M | -68.1% |
| Operating Free Cash Flow | -$107.30M | -81.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.22 | 1.58 | 1.81 | 2.06 | -31.48% |
| Price to Sales | 8.98 | 10.38 | 3094.13 | - | |
| Price to Tangible Book Value | 2.22 | 1.58 | 1.81 | 2.06 | -31.48% |
| Enterprise Value to EBITDA | -21.00 | -10.88 | -11.72 | -12.64 | -63.06% |
| Return on Equity | -37.4% | -35.2% | -39.7% | -44.4% | 26.65% |
| Total Debt | $54.32M | $48.63M | $46.56M | $44.40M | -15.45% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
